SynAct Pharma AB (DE:8F8)
FRANKFURT:8F8
8F8 Stock Chart & Stats
€2.08
€0.06(6.50%)
At close: 4:00 PM EST
€2.08
€0.06(6.50%)
Day’s Range― - ―
52-Week Range€1.22 - €2.32
Previous CloseN/A
Volume0.00
Average Volume (3M)89.00
Market Cap
€68.09M
Enterprise Value€860.54M
Total Cash (Recent Filing)€68.89M
Total Debt (Recent Filing)€1.54M
Price to Earnings (P/E)―
Beta0.45
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.01
Shares Outstanding53,330,242
10 Day Avg. Volume268
30 Day Avg. Volume89
Financial Highlights & Ratios
PEG Ratio-2.41
Price to Book (P/B)6.78
Price to Sales (P/S)0.00
P/FCF Ratio-11.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.14
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance-sheet FlexibilityVery low debt-to-equity (~1%) materially reduces solvency risk and interest burden, giving management durable financial flexibility. For a clinical-stage biotech this increases options to extend runway via equity or partnership deals without heavy fixed financing costs, supporting program continuity.
Focused Clinical-stage PipelineA clear strategic focus on a single, well-defined mechanism (resomelagon/AP1189 targeting inflammation) concentrates R&D resources and creates a distinct scientific position. That specialization can attract partners or acquirers, streamline regulatory strategy, and create durable value if clinical data validate the mechanism.
Lean Organizational StructureA very small headcount implies a lean cost base and potentially capital-efficient operations, which can extend cash runway per financing round. For early-stage drug developers, a compact team can lower fixed overhead, enabling spend to be directed primarily to critical clinical and regulatory activities.
Bears Say
Persistent Negative Cash Flow / Heavy Cash BurnSustained negative operating and free cash flow (near -97M in 2025) is a durable structural weakness: it forces recurring funding rounds or partner deals, creates dilution risk, and can constrain the ability to advance multiple programs or scale operations without material external financing.
Pre-revenue Business ModelNo product revenue means the firm's value and cash runway depend entirely on clinical progress and external financing. This creates long-term execution risk: setbacks in trials translate directly into funding needs, and there is no recurring cash generation to fund operations or reduce dilution pressure.
Declining Equity And Widening LossesA meaningful drop in shareholder equity and prior notes of widening net losses signal shrinking financial cushion. Over several quarters this structural trend pressures funding flexibility, heightens reliance on capital markets or partners, and raises the risk of dilutive or unfavorable financing terms.
SynAct Pharma AB News
8F8 FAQ
What was SynAct Pharma AB’s price range in the past 12 months?
SynAct Pharma AB lowest stock price was €1.22 and its highest was €2.32 in the past 12 months.
What is SynAct Pharma AB’s market cap?
SynAct Pharma AB’s market cap is €68.09M.
When is SynAct Pharma AB’s upcoming earnings report date?
SynAct Pharma AB’s upcoming earnings report date is Aug 20, 2026 which is in 76 days.
How were SynAct Pharma AB’s earnings last quarter?
SynAct Pharma AB released its earnings results on May 27, 2026. The company reported -€0.044 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.044.
Is SynAct Pharma AB overvalued?
According to Wall Street analysts SynAct Pharma AB’s price is currently Overvalued.
Does SynAct Pharma AB pay dividends?
SynAct Pharma AB does not currently pay dividends.
What is SynAct Pharma AB’s EPS estimate?
SynAct Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SynAct Pharma AB have?
SynAct Pharma AB has 53,330,242 shares outstanding.
What happened to SynAct Pharma AB’s price movement after its last earnings report?
SynAct Pharma AB reported an EPS of -€0.044 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 12.789%.
Which hedge fund is a major shareholder of SynAct Pharma AB?
Currently, no hedge funds are holding shares in DE:8F8
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SynAct Pharma AB
SynAct Pharma AB, through its subsidiary, SynAct Pharma ApS, develops medicines for acute deterioration in inflammatory diseases. The company is developing AP1189, a drug candidate for the treatment of rheumatoid arthritis and idiopathic membranous glomerulonephritis. It has a partnership with the University Of Örebro to study the reduction of inflammation in vascular disease. The company was founded in 2012 and is headquartered in Lund, Sweden.
Technical Analysis
Oncopeptides AB
―
Saniona AB
―
Ascelia Pharma AB
―
Guard Therapeutics International AB
―
Cantargia AB
―
Options Prices
Currently, No data available
---